0001656472-20-000012.txt : 20200302 0001656472-20-000012.hdr.sgml : 20200302 20200302162405 ACCESSION NUMBER: 0001656472-20-000012 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 EFFECTIVENESS DATE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 20677169 BUSINESS ADDRESS: STREET 1: 720 KING STREET W STREET 2: SUITE 320 CITY: TORONTO STATE: A6 ZIP: M5V 2T3 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 720 KING STREET W STREET 2: SUITE 320 CITY: TORONTO STATE: A6 ZIP: M5V 2T3 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 NT 10-K 1 cronos12b-25.htm NT 10-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 001-38403
CUSIP: 22717L1013
(Check One):
Form 10-K    
Form 20-F
 Form 11-K
Form 10-Q
 
Form 10-D
Form N-CEN
Form N-CSR
 

For Period Ended: December 31, 2019
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-Q
 
 

For the Transition Period Ended:
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Part II (except for Item 5) and certain exhibits in Part IV, Item 15, as specified in the Form 10-K filed as described below.
PART I – REGISTRANT INFORMATION
 
Cronos Group Inc.
 
Full Name of Registrant
 
 
 
 
 
 
Former Name if Applicable
 
 
 
 
720 King St. W., Suite 320
 
Address of Principal Executive Office (Street and Number)
 
 
 
 
Toronto, Ontario, M5V 2T3
 
City, State and Zip Code









PART II – RULES 12b-25 (b) and (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
 
 
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
 
 
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE
Cronos Group Inc. (the “Company”) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”), which is not complete as described therein. The Company is unable to file the complete Form 10-K at this time without unreasonable effort or expense because of delays in finalizing its audited financial statements. The Company has been unable to complete its financial statements for fiscal 2019 due to a continuing review by the Audit Committee of the Company’s Board of Directors, with the assistance of outside counsel and forensic accountants, of several bulk resin purchases and sales of products through the wholesale channel and the appropriateness of the recognition of revenue from those transactions. Accordingly, Part II (except for Item 5) and certain exhibits in Part IV, Item 15, as specified in the Form 10-K have been omitted from the Form 10-K. The Company intends to file a complete version of the Form 10-K with the SEC as soon as practicable and currently expects to do so within the fifteen-day extension period afforded by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. However, no assurance can be given that the Company will meet this deadline.

-2-



PART IV
OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
 
Xiuming Shum
(416)
504-0004
 
(Name)
(Area Code)
(Telephone Number)
 
 
 
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
 
Yes No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
Yes No
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

As outlined above in Part III of this Form 12b-25, the Company has not completed the preparation of its audited financial statements for the year ended December 31, 2019. Therefore, it is not possible to provide a reasonable estimate of the changes in results of operations from the corresponding period of the latest fiscal year. However, subject to finalization of its financial statements, the Company expects to report for fiscal 2019:
    an increase in net revenue;
    a material inventory write-down;
    a material decrease in gross profit;
    a material increase in operating loss;
    a material gain on revaluation of financial liabilities;
    restructuring charges; and
    a material increase in net income.


Cronos Group Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 2, 2020
By:
/s/ Michael Gorenstein
 
 
Michael Gorenstein
 
 
President & Chief Executive Officer


-3-